Isabel Ramírez
Isabel Ramírez has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Borja Otero
Spanish Menopause Society (Asociación Española para el Estudio de la Menopausia - AEEM), Spain; Sociedad Española de Ginecología y Obstetricia (SEGO), Spain
5 shared publications - Esther De la Viuda
Spanish Menopause Society (Asociación Española para el Estudio de la Menopausia - AEEM), Spain; Sociedad Española de Ginecología y Obstetricia (SEGO), Spain
5 shared publications - Laura Baquedano
Department of Obstetrics and Gynecology, Miguel Servet Hospital, 50009 Zaragoza, Spain
5 shared publications - Nicolás Mendoza
University of Granada
5 shared publications - Pluvio J. Coronado
Women Health Institute, Hospital Clínico San Carlos, IdISSC School of Medicine, Universidad Complutense de Madrid
5 shared publications - Plácido Llaneza
Spanish Menopause Society (Asociación Española para el Estudio de la Menopausia - AEEM), Spain; Sociedad Española de Ginecología y Obstetricia (SEGO), Spain
5 shared publications
Latest Publications
- Open Access
- 12 August 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (16) , 5263
Associations between Menopausal Hormone Therapy and Colorectal, Lung, or Melanoma Cancer Recurrence and Mortality: A Narrative Review
Objective: to develop eligibility criteria for use in non-gynecological cancer patients. Methods: We searched all the articles published in peer-reviewed journals up to March 2021. We utilized the PICOS standards and the following selection criteria: menopausal women with a history of non-gynecological and non-breast cancer who underwent hormone replacement therapy (HRT) using various preparations (oestrogens alone or in combination with a progestogen, tibolone, or tissue selective oestrogen complex) and different routes of administration (including oral, transdermal, vaginal, or intra-nasal). We focused on randomized controlled trials as well as relevant extension studies or follow-up reports, specifically examining recurrence and mortality outcomes. Results: Women colorectal cancer survivors who use MHT have a lower risk of death from any cause than those survivors who do not use MHT. Women who are skin melanoma survivors using MHT have a longer survival rate than non-MHT survivors. There is no evidence that women lung cancer survivors who use MHT have a different survival rate than those who do not use MHT. Conclusions: MHT is safe for women who have a history of colorectal, lung, or skin melanoma cancers.
- 12 August 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (16) , 5263
Open AccessAssociations between Menopausal Hormone Therapy and Colorectal, Lung, or Melanoma Cancer Recurrence and Mortality: A Narrative Review
Objective: to develop eligibility criteria for use in non-gynecological cancer patients. Methods: We searched all the articles published in peer-reviewed journals up to March 2021. We utilized the PICOS standards and the following selection criteria: menopausal women with a history of non-gynecological and non-breast cancer who underwent hormone replacement therapy (HRT) using various preparations (oestrogens alone or in combination with a progestogen, tibolone, or tissue selective oestrogen complex) and different routes of administration (including oral, transdermal, vaginal, or intra-nasal). We focused on randomized controlled trials as well as relevant extension studies or follow-up reports, specifically examining recurrence and mortality outcomes. Results: Women colorectal cancer survivors who use MHT have a lower risk of death from any cause than those survivors who do not use MHT. Women who are skin melanoma survivors using MHT have a longer survival rate than non-MHT survivors. There is no evidence that women lung cancer survivors who use MHT have a different survival rate than those who do not use MHT. Conclusions: MHT is safe for women who have a history of colorectal, lung, or skin melanoma cancers.
- Open Access
- 21 June 2023
- Published by MDPI AG in Preprints.org
Associations Between Menopausal Hormone Therapy and Colorectal, Lung or Melanoma Cancer Recurrence and Mortality: A Systematic Reviews and Meta-Analysis
Objective: to create a set of eligibility criteria for the use of MHT in non-gynecological cancer patients. Methods: We searched all articles published in peer-reviewed journals up to March 2021. The PICOS standards were used and the selection criteria as follows: menopausal women of any age with non-gynecological and non-breast cancer receiving HMT, any MHT preparation (oestrogens alone or combined with a progestogen, tibolone or tissue selective oestrogen complex) or any route of administration (oral, transdermal, vaginal or intra-nasal), recurrence and mortality, randomized controlled trials, and related extension studies or follow-up reports. Results: Women colorectal cancer survivors who use MHT have a lower risk of death from any cause than those survivors who do not use MHT. Women Skin Melanoma Survivors Using MHT Have Longer Survival than Non-MHT Survivors. There is no evidence that women lung cancer survivors who use MHT have a different survival rates than those survivors who do not use MHT. Conclusion: MHT is safe in women who have suffered from colorectal, lung or skin melanoma cancers The study was registered at www.prospero.org (CRD42020166658)
- 21 June 2023
- Published by MDPI AG in Preprints.org
Open AccessAssociations Between Menopausal Hormone Therapy and Colorectal, Lung or Melanoma Cancer Recurrence and Mortality: A Systematic Reviews and Meta-Analysis
Objective: to create a set of eligibility criteria for the use of MHT in non-gynecological cancer patients. Methods: We searched all articles published in peer-reviewed journals up to March 2021. The PICOS standards were used and the selection criteria as follows: menopausal women of any age with non-gynecological and non-breast cancer receiving HMT, any MHT preparation (oestrogens alone or combined with a progestogen, tibolone or tissue selective oestrogen complex) or any route of administration (oral, transdermal, vaginal or intra-nasal), recurrence and mortality, randomized controlled trials, and related extension studies or follow-up reports. Results: Women colorectal cancer survivors who use MHT have a lower risk of death from any cause than those survivors who do not use MHT. Women Skin Melanoma Survivors Using MHT Have Longer Survival than Non-MHT Survivors. There is no evidence that women lung cancer survivors who use MHT have a different survival rates than those survivors who do not use MHT. Conclusion: MHT is safe in women who have suffered from colorectal, lung or skin melanoma cancers The study was registered at www.prospero.org (CRD42020166658)